Back

Troponin-stratified outcomes of extended clopidogrel monotherapy versus dual antiplatelet therapy in acute coronary syndrome: insights from the OPT-BIRISK randomized trial

28 August 2026 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Contemporary pharmacotherapy after acute coronary syndromes: beta-blockers, lipids, and platelet inhibition Antiplatelet Drugs ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Miaohan Qiu

General Hospital of Northern Theater Command, Shenyang (China)

7 More presentations in this session

Presentation thumbnail
Effect of beta-blockers on cardiovascular hospitalisation after myocardial infarction: A substudy of the BETAMI-DANBLOCK trial.
Doctor H. Caglar (Copenhagen, DK)
Abstract Slides
Presentation thumbnail
Coordinated post-myocardial infarction care versus the PCSK9 modulator drug program: a comparative outcomes study
Professor M. Banach (Lodz, PL)
Abstract Slides
Presentation thumbnail
Long-term effect of beta-blockers after myocardial infarction with preserved left ventricular ejection fraction in a per protocol analysis of the REDUCE-AMI trial
Professor T. Jernberg (Stockholm, SE)
Abstract Slides
Presentation thumbnail
Long-term clinical outcomes of beta-blocker therapy in elderly patients with preserved left ventricular function after percutaneous coronary intervention for acute myocardial infarction
Assistant Professor J. Choe (Pusan, KR)
Abstract Slides
Presentation thumbnail
Impact of stepwise dual antiplatelet therapy de-escalation in patients with high bleeding risk undergoing drug-coated balloon angioplasty: Insights from the REC-CAGEFREE II trial
Associate Professor C. Gao (Hefei, CN)

Access the full session

Session thumbnail
Contemporary pharmacotherapy after acute coronary syndromes: beta-blockers, lipids, and platelet inhibition

The Event

Event poster

ESC Congress 2026

28 August 2026 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Aspirin versus clopidogrel beyond 1 month after acute coronary syndrome with high bleeding risk or ST-elevation myocardial infarction: pre-specified subanalyses of the STOPDAPT-3
1 September 2025
thumbnail
Webinar
ACVC Biomarker Talk Series - Inventor and innovator - cardiac troponin T
21 December 2022
thumbnail
Congress Presentation
Extended clopidogrel monotherapy versus DAPT in high-risk patients: the OPT-BIRISK trial
28 August 2023
thumbnail
Congress Presentation
PCSK9 inhibitors and cardiovascular outcomes in AMI-BIRISK patients: a multicenter retrospective study
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources